Show simple item record

dc.contributor.authorFeeney, Laura
dc.contributor.authorJain, Yatin
dc.contributor.authorBeasley, M.
dc.contributor.authorDonnelly, O.
dc.contributor.authorKong, A.
dc.contributor.authorMoleron, R.
dc.contributor.authorNallathambi, C.
dc.contributor.authorRolles, M.
dc.contributor.authorSanghera, P.
dc.contributor.authorTin, A.
dc.contributor.authorUlahannan, D.
dc.contributor.authorWalter, H. S.
dc.contributor.authorWebster, R.
dc.contributor.authorMetcalf, Robert
dc.date.accessioned2021-09-30T11:56:03Z
dc.date.available2021-09-30T11:56:03Z
dc.date.issued2021en
dc.identifier.citationFeeney L, Jain Y, Beasley M, Donnelly O, Kong A, Moleron R, et al. Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma. Cancers. 2021 Aug 27;13(17):4336.en
dc.identifier.pmid34503145en
dc.identifier.doi10.3390/cancers13174336en
dc.identifier.urihttp://hdl.handle.net/10541/624604
dc.description.abstractAdenoid cystic carcinoma (ACC) is a rare cancer of secretory glands. Recurrent or metastatic (R/M) ACC is generally considered resistant to cytotoxic chemotherapy. Recent phase II studies have reported improved objective response rates (ORR) with the use of the multi-kinase inhibitor lenvatinib. We sought to evaluate real-world experience of R/M ACC patients treated with lenvatinib monotherapy within the UK National Health Service (NHS) to determine the response rates by Response Evaluation Criteria of Solid Tumour (RECIST) and clinical outcomes. Twenty-three R/M ACC patients from eleven cancer centres were included. All treatment assessments for clinical decision making related to drug therapy were undertaken at the local oncology centre. Central radiology review was performed by an independent clinical trial radiologist and blinded to the clinical decision making. In contrast to previously reported ORR of 12-15%, complete or partial response was not observed in any patients. Eleven patients (52.4%) had stable disease and 5 patients (23.8%) had progression of disease as the best overall response. The median time on treatment was 4 months and the median survival from discontinuation was 1 month. The median PFS and OS from treatment initiation were 4.5 months and 12 months respectively. Multicentre collaborative studies such as this are required to evaluate rare cancers with no recommended standard of care therapy and variable disease courses.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.3390/cancers13174336en
dc.titleCentralised RECIST assessment and clinical outcomes with lenvatinib monotherapy in recurrent and metastatic adenoid cystic carcinomaen
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UKen
dc.identifier.journalCancersen
dc.description.noteen]
refterms.dateFOA2021-10-13T08:22:11Z


Files in this item

Thumbnail
Name:
34503145.pdf
Size:
2.348Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record